Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats
Please enable JavaScript to view this page.
GIP1-39, a novel insulinotropic peptide form and aspects on its mechanism of action
Tin Wui Wong Lijing Wang College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, Peoples Republic of China Correspondence: Lijing Wang, College of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing, Jiangsu, Peoples Republic of China, Tel +86 182 860 69474, Email [email protected]
Safety-first, evidence-forward guidance for GLP-1s
GLP-1 receptor agonists enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, all mechanisms that help control glucose while also promoting satiety and caloric reduction